CSIMarket
 
Iovance Biotherapeutics Inc   (IOVA)
Other Ticker:  
 
 


 
 IOVA $13.9100 $-0.3000 -2.11%

 Volume (M): 18,150   Open : 14.07    52 Wk Avg :  7.30

 
 IOVA $13.9100 $-0.3000 -2.11%

 Volume (M): 18,150   Open : 14.07    52 Wk Avg :  7.30




IOVA Today's High: $14.39 IOVA Shares One Week Perf: -7.88 %
IOVA Today's Low: $ 13.68 IOVA Shares 30 Day Performance: 45.65 %
Number of IOVA Shares Traded (M): 18,150 IOVA Share Price 52 Wk High: $ 18.33
Value of IOVA's Shares Traded (M$): $ 252,462 IOVA Share Price 52 Wk Avg: $7.30
Share Price at the Open: $14.07 IOVA's Share Price 52 Wk Low: $3.21



  News about Iovance Biotherapeutics Inc's Stock Splits and Dividends

Iovance Biotherapeutics, Inc.: Fostering Innovations in TIL Therapies for Cancer Patients



In a recent press release, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a leading biotechnology company, announced the pricing of an underwritten offering of its common stock. This offering is expected to generate approximately $211 million in gross proceeds for Iovance. The funds raised will support the company's continued efforts in developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients battling cancer. Additionally, Iovance Biotherapeutics had previously granted stock options to non-executive employees as part of its growth strategy to attract and retain top talent.
Underwritten Offering Details:
The underwritten offering consists of 23,014,000 shares of Iovance's common stock, priced at $9.15 per share. With the expected gross proceeds of $211 million, the company plans to allocate the funds towards advancing its TIL therapies and other innovative cancer treatment research. The offering is slated to close on or around February 22, 2024, subject to customary closing conditions.

Iovance Biotherapeutics Bolsters Team and Shareholder Value Through Inducement Stock Options Grants

Iovance Biotherapeutics Continues to Expand Team and Enhance Shareholder Value Through Inducement Stock Options Grants
SAN CARLOS, Calif., Feb. 16, 2024 - Iovance Biotherapeutics, a biotechnology company specializing in TIL therapies for cancer patients, recently announced inducement stock options grants to sixteen new non-executive employees. This move comes on the heels of the company's continued efforts to expand its team and drive future growth and shareholder value.
The inducement stock options, covering a total of 40,450 shares of Iovance's common stock, were approved on February 15, 2024. This strategic decision aims to attract and retain top talent within the organization, paving the way for innovation and advancement in the field of cancer therapeutics.

Iovance Biotherapeutics Empowers Workforce with Inducement Grants to Drive Growth



In a recent press release, Iovance Biotherapeutics, a leading biotechnology company dedicated to developing groundbreaking polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has announced the approval of inducement stock options for four new non-executive employees. This move aims to enhance employee retention, promote growth, and ultimately drive the company's mission forward. With 245.817 million shares outstanding and a current stock price of $7.89, let's delve into the facts and assess the potential impact of these grants on Iovance Biotherapeutics' shares.
1. Inducement Grants:
On December 21, 2023, Iovance Biotherapeutics approved the grant of inducement stock options, encompassing 44,175 shares of the company's common stock. These options were exclusively allocated to the company's new non-executive employees, signifying Iovance's focus on attracting and retaining top talent. With these grants, Iovance aims to incentivize hard work, commitment, and dedication, driving the growth and success of the company.

Iovance Biotherapeutics Expands Workforce and Motivates Talent with Inducement Stock Options, Marking a Leap Forward in Cancer Treatment Innovation

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Oct. 20, 2023 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a leading biotechnology company specializing in the innovation, development, and delivery of novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, has recently made an announcement regarding inducement stock options. In alignment with NASDAQ Listing Rule 5635(c)(4), the company granted a total of 48,300 stock options to ten newly recruited non-executive employees on October 20, 2023.
These recent grants solidify Iovance Biotherapeutics' commitment to expanding their team and paving the way for future growth and shareholder value. Just a month earlier, on September 22, 2023, the company made headlines by expanding their team through the use of inducement stock options. This move was seen as a strategic step to enhance their workforce and seize opportunities in the competitive biotechnology landscape.

Iovance Biotherapeutics Expands Team with Inducement Stock Options, Paving the Way for Future Growth and Shareholder Value


Iovance Biotherapeutics Grants Inducement Stock Options to New Employees, Impact on Share Price
SAN CARLOS, Calif., Sept. 22, 2023 - Iovance Biotherapeutics, a leading biotechnology company focusing on pioneering polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, announced the approval of inducement stock options for eleven new non-executive employees. On September 21, 2023, the company granted a total of 174,400 shares of common stock as part of these inducement grants.
The purpose of offering inducement grants is to attract top talent and incentivize new employees to contribute to the company's goals. By providing stock options, Iovance Biotherapeutics aims to align the interests of these employees with the long-term success of the company. As the stock options vest over time, it motivates employees to stay with the company and actively participate in its growth.





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com